HR Execs on the Move


 
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.cytomx.com
  • 151 Oyster Point Boulevard Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.515.3185

Executives

Name Title Contact Details
Matt Paulson
Development Chief of Staff Profile
Lindsay Yamamoto
Director, Human Resources Profile
Danielle Olander
Senior Vice President, Talent and Systems Development Profile

Similar Companies

Ludesi

Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.

Q Bio

Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.

Cofactor Genomics

Cofactor Genomics is pioneering the use of RNA to diagnose disease.

Intabio

Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.